Clinical Trials
3
2 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Active, not recruiting
1
33.3%
Completed
1
33.3%
Enrolling By Invitation
1
33.3%
No approval data available
- Head and neck squamous cell carcinoma cases are projected to increase from 229,000 to 273,000 across eight major markets by 2034, with frail and elderly patients representing 44% of cases. - Three emerging therapies—JNJ-1900, Akalux, and Steboronine—offer new treatment options for patients who cannot tolerate intensive surgery, radiation, and platinum-based chemotherapy. - JNJ-1900 is positioned for broadest global impact with projected sales of $108 million by 2034, while Akalux targets $77.6 million in sales across the same timeframe. - These treatments focus on improving locoregional control while minimizing systemic toxicity that makes standard regimens intolerable for vulnerable patient populations.
- The National Cancer Center Japan will conduct a Phase I/II basket trial of Boron Neutron Capture Therapy (BNCT) for unresectable and recurrent thoracic malignant solid tumors. - This trial is the first of its kind to evaluate BNCT across multiple thoracic cancer types, aiming to expedite development by grouping cancers with shared organs at risk. - The study will assess the safety and efficacy of BNCT, along with the utility of [18F]F-BPA PET imaging in determining patient suitability for BNCT. - The collaboration involves Sumitomo Heavy Industries, STELLA PHARMA CORPORATION, and Cancer Intelligence Care Systems, with the trial period extending until October 2028.
